Publications by authors named "F Correard"
Article Synopsis
- Some patients with metastatic melanoma (a type of skin cancer) don't get better from usual treatments. Scientists are looking at personalized medicine, which means tailoring treatment to the patient’s specific cancer.
- In a study, 26 patients who found specific genetic changes in their cancer received personalized treatments, with some seeing good results.
- The study showed that using advanced testing followed by targeted therapy might help patients whose melanoma didn't respond to regular treatments.
Azacitidine (Aza) is a mainstay of treatment for patients with acute myeloid leukaemia (AML) ineligible for induction chemotherapy and other high-risk myelodysplastic syndromes (MDS). Only half of patients respond, and almost all will eventually relapse. There are no predictive markers of response to Aza.
View Article and Find Full Text PDFThe therapeutic management of gliomas remains particularly challenging. Brain tumors present multiple obstacles that make therapeutic innovation complex, mainly due to the presence of blood-tumor and blood-brain barriers (BTB and BBB, respectively) which prevent penetration of anticancer agents into the brain parenchyma. Focused ultrasound-mediated BBB disruption (FUS-BBBD) provides a physical method for non-invasive, local, and reversible BBB disruption.
View Article and Find Full Text PDFArticle Synopsis
- * Conducted in three French hospitals from February 2021 to February 2022, the research analyzed the outcomes of 235 hospitalized COVID-19 patients, matching them to reduce bias in treatment allocation.
- * Results indicated that both medications had similar effects on 28-day mortality rates, in-hospital mortality, oxygen requirements, ICU admissions, and secondary infection rates, suggesting comparable safety and efficacy.